Holen Sie sich die Stockscreener-App
198.64
0.00%
0.00
Vorhandelsmarkt:
198.56
-0.08
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$198.64
Offen:
$198.09
24-Stunden-Volumen:
3.05M
Relative Volume:
0.50
Marktkapitalisierung:
$350.91B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.76B
KGV:
94.59
EPS:
2.1
Netto-Cashflow:
$18.24B
1W Leistung:
+0.05%
1M Leistung:
+3.22%
6M Leistung:
+2.92%
1J Leistung:
+4.45%
1-Tages-Spanne:
$197.05
$200.02
1-Wochen-Bereich:
$194.67
$200.33
52-Wochen-Spanne:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Stock Analysis | Abbvie OutlookBalancing Strong Fundamentals with Mixed Technical and Flow Signals - AInvest
With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight - insights.citeline.com
AbbVie To Invest $195 Mln In Illinois API Manufacturing Expansion - Nasdaq
C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Novartis, Apollomics Inc., Abbvie, Janssen Research and Developm - Barchart.com
AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition (NYSE:ABBV) - Seeking Alpha
AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients - Yahoo Finance
AbbVie details nearly $200M API plant as part of new US investments - Endpoints News
AbbVie to invest $195M in North Chicago manufacturing expansion - The Business Journals
Illinois secures AbbVie’s $195 million investment for North Chicago facility - MyStateline
AbbVie to invest $195M to build plant in Illinois - MSN
AbbVie to invest $195M to build plant in Illinois (ABBV:NYSE) - Seeking Alpha
AbbVie investing $195 million to expand manufacturing footprint in Illinois - Daily Herald
AbbVie to invest $195 million in expanding Illinois facility - WICS
AbbVie plans $195M expansion of North Chicago plant in U.S. production push - Crain's Chicago Business
AbbVie plans $195M API plant in Illinois as part of US investment campaign - Fierce Pharma
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. - Investing News Network
AbbVie announces $195 mln investment to expand active pharmaceutical ingredient manufacturing in U.S. - MarketScreener
AbbVie Invests $195 Million to Construct New Manufacturing Facility in Illinois - MarketScreener
AbbVie's Strategic API Expansion and U.S. Supply Chain Resilience: A New Era for Pharmaceutical Sector Valuation - AInvest
AbbVie to invest $195 million in North Chicago manufacturing expansion By Investing.com - Investing.com Canada
AbbVie invests $195 million in US manufacturing facility expansion - StreetInsider
Short Bowel Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire, AbbVie, Hanmi Pharma - Barchart.com
Piper Sandler starts AbbVie as it sees growth shielded from drug patent losses - Investing.com Canada
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Autoinjectors Market Set to Surpass USD 3.02 Billion by 2030 as Demand for Advanced Drug Delivery Systems Accelerates | MarketsandMarkets™. - GlobeNewswire Inc.
AbbVie Gains New Bullish Coverage As Stock Looks To Test $200 - AskTraders.com
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - uk.finance.yahoo.com
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - GlobeNewswire
AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments - TipRanks
Piper Sandler assumes coverage of Abbvie stock with Overweight rating By Investing.com - Investing.com Canada
AbbVie Surges 0.3% on Earnings and Acquisition Hopes as $1.2B Volume Hits Top 500 Rank - AInvest
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
AbbVie’s upadacitinib raises the bar for alopecia areata - Yahoo Finance
4 Overlooked Dividend Aristocrat Stocks with Up To 60%+ Growth Potential - 24/7 Wall St.
AbbVie’s Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment - Insider Monkey
AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN
This Insider Has Just Sold Shares In AbbVie - simplywall.st
AbbVie’s Upcoming Study on ABBV-932: What Investors Need to Know - TipRanks
AbbVie's $0.81B Volume Ranks 104th as Stock Falls 0.41% on Mixed Earnings and Analyst Upgrades - AInvest
AbbVie-Genmab cancer collab shows promising results - Crain's Chicago Business
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win - insights.citeline.com
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules - Benzinga
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
AbbVie and Genmab’s Promising B-Cell Lymphoma Trial: A Potential Game-Changer? - The Globe and Mail
AbbVie and Genmab’s Promising Phase 3 Trial for Follicular Lymphoma - The Globe and Mail
AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment - TipRanks
AbbVie Advances Glaucoma Treatment with XEN63 Gel Stent Study - TipRanks
AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa - TipRanks
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):